Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Paul T. Heath, Eva Galiza, D. N. Baxter, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. 398-407
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
Eddie Underwood, Lisa M. Dunkle, Shabir A. Madhi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 501-517
Open Access | Times Cited: 24
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
Cheng-Yi Lee, Hung-Wei Kuo, Yulun Liu, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 3
Open Access | Times Cited: 7
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Tanmay Ghildiyal, Nishant Rai, Janhvi Mishra Rawat, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-19
Open Access | Times Cited: 6
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial
Meagan E. Deming, Elizabeth R. Brown, Monica A. McArthur, et al.
The Lancet Microbe (2025), pp. 100984-100984
Open Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
Clive Pritchard, Lucie Kutikova, Richard Pitman, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 187-187
Open Access
New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons
Pilar Arrazola, María Fernández Prada, Ángel Gil, et al.
Enfermedades infecciosas y microbiologia clinica (English ed ) (2025) Vol. 43, Iss. 1, pp. 36-46
Open Access
Assessing the effectiveness of vaccination strategies against respiratory pathogens⁠
Mohammad Puad Abdullah, Faisal M. Alanazi, Saad F. Gandurah, et al.
International Journal of Community Medicine and Public Health (2025)
Open Access
CT scan-derived pectoralis muscle parameters are closely associated with COVID-19 outcomes: A systematic review and meta-analysis
Wen Zhang, Tao Wang, Sha Luo, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316893-e0316893
Open Access
Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
Ranjan K. Mohapatra, Ahmed Mahal, L. V. Simhachalam Kutikuppala, et al.
Frontiers in Virology (2022) Vol. 2
Open Access | Times Cited: 19
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece
Helena C. Maltezou, Dimitrios Basoulis, Konstantinos Bonelis, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2343-2348
Open Access | Times Cited: 11
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Traci L. Bricker, Astha Joshi, Nadia Soudani, et al.
Journal of Virology (2024) Vol. 98, Iss. 3
Open Access | Times Cited: 3
Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Adrianus C. M. Boon, Nadia Soudani, Traci L. Bricker, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 3
The extent and impact of vaccine status miscategorisation on covid-19 vaccine efficacy studies
Martin Neil, Scott McLachlan, Norman Fenton
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Nadia Soudani, Traci L. Bricker, Tamarand L. Darling, et al.
Journal of Virology (2024)
Open Access | Times Cited: 3
COVID-19 Vaccination and Alcohol Consumption: Justification of Risks
Pavel Solopov
Pathogens (2023) Vol. 12, Iss. 2, pp. 163-163
Open Access | Times Cited: 9
COVID-19 Vaccines: Where Do We Stand at the End of 2023?
Kenneth Lundström
(2024)
Open Access | Times Cited: 3
From rejection to the Nobel Prize: Karikó and Weissman’s pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology
Amit Bansal
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany
Lucie Kutikova, James T. Brash, Kawitha Helme, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 387-387
Open Access | Times Cited: 2
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations
Qian Gui, Cuige Gao, Miaomiao Zhang, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 579-579
Open Access | Times Cited: 2
Scalable bioprocess for high-yield production of SARS-CoV-2 trimeric spike protein-based immunogen (IMT-CVAX) using suspension CHO cells
Sneha Singh, B. Vikram Kumar, Jitender, et al.
Process Biochemistry (2024) Vol. 147, pp. 332-346
Closed Access | Times Cited: 2
An overview of protein-based SARS-CoV-2 vaccines
Yogesh R. Suryawanshi
Vaccine (2023) Vol. 41, Iss. 42, pp. 6174-6193
Closed Access | Times Cited: 6
A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants
Gan Zhao, Zhiyu Zhang, Yuan Ding, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 513-513
Open Access | Times Cited: 5
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults
Prasad S. Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top